Aarti Drugs Limited has released its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated annual revenue of ₹2,56,531 lakhs with a net profit of ₹19,494 lakhs. Additionally, the Board approved the re-appointment of key auditors and reconstituted its Risk Management Committee, inducting Shri Narendra J. Salvi as a member effective May 15, 2026.
Financial Performance Overview
For the fiscal year ended March 31, 2026, Aarti Drugs Limited delivered a robust financial performance. The company’s consolidated annual revenue reached ₹2,56,531 lakhs, compared to ₹2,38,703 lakhs in the previous year. The net profit attributable to the owners of the company for the same period stood at ₹19,492 lakhs, showcasing steady operational growth despite market challenges.
Leadership and Governance Updates
The Board of Directors, at its meeting held on May 15, 2026, focused on strengthening corporate governance. The Risk Management Committee has been reconstituted with the inclusion of Shri Narendra J. Salvi, a Non-Executive, Non-Independent Director, effective immediately.
Strategic Appointments
The company also finalized its audit appointments for the upcoming fiscal periods to ensure continued financial transparency:
- Cost Auditor: M/s GMVP & Associates LLP has been re-appointed as the Cost Auditor for the financial year ending March 31, 2027.
- Internal Auditor: M/s Raman S. Shah & Co. has been re-appointed as the Internal Auditor for a tenure of three consecutive years, starting from April 1, 2026.
Audit Integrity
The company confirmed that its statutory auditors, Gokhale & Sathe, Chartered Accountants, have issued an un-modified opinion on both the standalone and consolidated financial results for the financial year ended March 31, 2026, reinforcing the company’s commitment to high standards of financial reporting.
Source: BSE
